IDYA vs. XENE, SMMT, BHVN, RARE, CORT, ARWR, PBH, TGTX, MOR, and RNA
Should you be buying IDEAYA Biosciences stock or one of its competitors? The main competitors of IDEAYA Biosciences include Xenon Pharmaceuticals (XENE), Summit Therapeutics (SMMT), Biohaven (BHVN), Ultragenyx Pharmaceutical (RARE), Corcept Therapeutics (CORT), Arrowhead Pharmaceuticals (ARWR), Prestige Consumer Healthcare (PBH), TG Therapeutics (TGTX), MorphoSys (MOR), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical preparations" industry.
Xenon Pharmaceuticals (NASDAQ:XENE) and IDEAYA Biosciences (NASDAQ:IDYA) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, community ranking, media sentiment and profitability.
Xenon Pharmaceuticals has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.
95.5% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 5.4% of Xenon Pharmaceuticals shares are held by company insiders. Comparatively, 3.5% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Xenon Pharmaceuticals has a net margin of 0.00% compared to Xenon Pharmaceuticals' net margin of -483.05%. Xenon Pharmaceuticals' return on equity of -20.09% beat IDEAYA Biosciences' return on equity.
Xenon Pharmaceuticals presently has a consensus target price of $59.11, indicating a potential upside of 46.53%. IDEAYA Biosciences has a consensus target price of $46.80, indicating a potential upside of 12.69%. Given IDEAYA Biosciences' higher probable upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than IDEAYA Biosciences.
IDEAYA Biosciences has higher revenue and earnings than Xenon Pharmaceuticals. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Xenon Pharmaceuticals received 294 more outperform votes than IDEAYA Biosciences when rated by MarketBeat users. Likewise, 69.39% of users gave Xenon Pharmaceuticals an outperform vote while only 67.86% of users gave IDEAYA Biosciences an outperform vote.
In the previous week, IDEAYA Biosciences had 3 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 26 mentions for IDEAYA Biosciences and 23 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.62 beat IDEAYA Biosciences' score of 0.47 indicating that IDEAYA Biosciences is being referred to more favorably in the news media.
Summary
IDEAYA Biosciences beats Xenon Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get IDEAYA Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IDYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IDEAYA Biosciences Competitors List
Related Companies and Tools
